Technical Analysis for RVPH - Reviva Pharmaceuticals Holdings, Inc.

Grade Last Price % Change Price Change
F 3.08 -2.22% -0.07
RVPH closed down 2.22 percent on Monday, March 18, 2024, on 72 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 28
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -2.22%
Lower Bollinger Band Walk Weakness -2.22%
New 52 Week Low Weakness -2.22%

   Recent Intraday Alerts

Alert Time
Down 3% about 21 hours ago
Gap Up Closed about 21 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Inflammatory Diseases Schizophrenia Major Depressive Disorder Psychiatric Diagnosis Psychiatry Stage Pharmaceutical Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Chloroarenes Bipolar Disorder Pulmonary Hypertension Treatment Of Schizophrenia Piperazines

Is RVPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.2499
52 Week Low 2.8
Average Volume 308,691
200-Day Moving Average 4.62
50-Day Moving Average 3.99
20-Day Moving Average 3.73
10-Day Moving Average 3.36
Average True Range 0.26
RSI (14) 31.51
ADX 25.12
+DI 15.39
-DI 29.53
Chandelier Exit (Long, 3 ATRs) 3.81
Chandelier Exit (Short, 3 ATRs) 3.58
Upper Bollinger Bands 4.67
Lower Bollinger Band 2.79
Percent B (%b) 0.16
BandWidth 50.37
MACD Line -0.30
MACD Signal Line -0.22
MACD Histogram -0.079
Fundamentals Value
Market Cap 85.99 Million
Num Shares 27.9 Million
EPS -1.68
Price-to-Earnings (P/E) Ratio -1.83
Price-to-Sales 0.00
Price-to-Book 69.86
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.58
Resistance 3 (R3) 3.61 3.48 3.49
Resistance 2 (R2) 3.48 3.35 3.46 3.46
Resistance 1 (R1) 3.28 3.28 3.22 3.25 3.44
Pivot Point 3.15 3.15 3.12 3.13 3.15
Support 1 (S1) 2.95 3.02 2.89 2.92 2.72
Support 2 (S2) 2.82 2.95 2.80 2.70
Support 3 (S3) 2.62 2.82 2.67
Support 4 (S4) 2.59